Geoffrey von Maltzahn



Geoffrey von Maltzahn joined Flagship Pioneering in 2009 and serves as partner. He is an inventor, entrepreneur, and the co-founder of multiple groundbreaking companies in healthcare, nutrition and agriculture.

Through his role in Flagship VentureLabs, Geoffrey has co-founded companies that have, in aggregate, achieved over $3 billion in public and private market capitalization. These companies include Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), Axcella Health and Kaleido Biosciences, which, respectively, are pioneering plant microbiome products for crop improvement, microbiome therapeutics, amino acid-based drugs, and novel chemistries to shape the human microbiome.

Geoffrey currently serves as chief executive officer of Kaleido Biosciences and chief innovation officer of Indigo. He recently also served as president of Indigo, where he led the development of the company’s plant microbiome platform, the growth of the world’s largest plant microbiome database, and the development of the company’s first commercial products: Indigo Cotton and Indigo Wheat. Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform. He has also served as vice president of discovery of Axcella, where he led the discovery of two therapeutic products in human trials.

Geoffrey has deep expertise in the microbiome, bioengineering and nanotechnology, and he has been recognized with numerous patent grants, awards, and publications. He is an inventor on over 100 patent applications and patents, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received over 20 awards and honors, including: the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; the Harvard-MIT Martha Gray Prize; and the Randolph G. Wei Award, which is awarded for MIT’s most outstanding contribution at the interface of life sciences and engineering undergraduate research. Geoff also has had his inventions profiled by Forbes, the Economist, CNN, Scientific American, Popular Sciences, MIT Technology Review, and many others.

Geoffrey was awarded a Ph.D. in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, M.D., Ph.D.; a M.S. in bioengineering from the University of California, San Diego; and a S.B. in chemical engineering from MIT.

Geoffrey von Maltzahn